CSPG4 has been studied as a target antigen in cancer immunotherapy based on its limited expression level in normal tissues and overexpression and supporting roles in cancer progression and invasion in various types of neoplasms, including TNBC (137). This evidence concerns the gene CSPG4 and cancer.